EDV Technology

EnGeneIC's technology platform, EDV™ utilizes antibody-targeted, non-living "nanocells" to release their payload directly into tumor cells. In doing so, EDV™ nanocells allow the use of very potent drugs and are far less toxic, while also offering a potential new means for treating drug-resistant cancers and stimulating a potent anti-tumor immune response.

EnGeneIC's technology platform, EDV™ utilizes antibody-targeted, non-living "nanocells" to release their payload directly into tumor cells. In doing so, EDV™ nanocells allow the use of very potent drugs and are far less toxic, while also offering a potential new means for treating drug-resistant cancers and stimulating a potent anti-tumor immune response.